Researcher
Simon De Meyer
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Cardiovascular Sciences, Kulak Kortrijk Campus (Department)
Responsible
From1 Aug 2015 → Today - Cardiovascular Sciences, Kulak Kortrijk Campus (Department)
Member
From1 Jan 2013 → Today - Biomedical Sciences Group, Kulak Kortrijk Campus (Section)
Member
From1 Oct 2012 → 31 Dec 2012 - Chemistry, Kulak Kortrijk Campus (Department)
Member
From1 Oct 2010 → 30 Sep 2012 - Faculty of Science, Kulak Kortrijk Campus (Faculty)
Member
From1 Oct 2001 → 30 Sep 2010
Projects
1 - 10 of 43
- Universal Chimeric Antigen Receptor (UniCAR) T-cell therapy: an innovative treatment for autoimmune diseaseFrom5 Apr 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Universal chimeric antigen receptor (uniCAR)-T cell therapy to treat autoimmune diseases: immune mediated thrombotic thrombocytopenic purpura as a model system.From1 Mar 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Endothelium-targeted gene therapy for von Willebrand disease using a hybrid adeno-transposon strategyFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Flow cytometer for the Interdisciplinary Research Facility Life Sciences at Campus Kulak KortrijkFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Towards improved thrombolysis in acute ischemic strokeFrom1 Jan 2021 → 31 Oct 2021Funding: BOF - postdoctoral mandates
- Light sheet microscopy for interdisciplinary research in life sciencesFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- Development and validation of a novel platform for fast and easy diagnosis of von Willebrand diseaseFrom1 Jan 2021 → 31 Dec 2022Funding: IOF - technology validation in lab
- Towards improved thrombolysis in ischemic stroke exploring novel therapeutic targetsFrom15 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development of a microfluidic platform for self-governing selection of individual B-cells using bioresponsive hydrogels: a source of fully human therapeutic antibodiesFrom20 Aug 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Thrombosis in COVID-19:dysregulation of the tromboinflammatory VWF/ADAMTS13 axis?From1 Apr 2020 → 31 Mar 2021Funding: IOF - technology validation in lab
Publications
41 - 50 of 141
- Neutrophil Extracellular Traps in Arterial and Venous Thrombosis(2019)
Authors: Kim Martinod, Simon De Meyer
Pages: 86 - 93 - The VWF/ADAMTS13 Axis in Cerebral Ischemia/Reperfusion Injury(2019)
Authors: Simon De Meyer
Pages: 25 - 25 - von Willebrand factor deficiency does not influence angiotensin II-induced abdominal aortic aneurysm formation in mice(2018)
Authors: Irina Portier, Kim Martinod, Hans Deckmyn, Karen Vanhoorelbeke, Simon De Meyer
- Clot Pathophysiology Why Is It Clinically Important?(2018)
Authors: Simon De Meyer
Pages: 611 - 623 - Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/ R660K/Y661F/Y665F) against platelet agglutination invitro and in a murine model of acute ischemic stroke(2018)
Authors: Frederik Denorme, Simon De Meyer
Pages: 2289 - 2299 - Improved molecular platform for the gene therapy of rare diseases by liver protein secretion(2018)
Authors: Karen Vanhoorelbeke, Simon De Meyer
Pages: 723 - 728 - Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.(2018)
Authors: Elien Roose, Kadri Kangro, An-Sofie Schelpe, Daan Dierickx, Hans Deckmyn, Simon De Meyer, Karen Vanhoorelbeke
Pages: 1729 - 1742 - Deletion of GARP on mouse regulatory T cells is not sufficient to inhibit the growth of transplanted tumors(2018)
Authors: Elien Vermeersch, Conny Gysemans, Karen Vanhoorelbeke, Simon De Meyer, Wim Maes, Hans Deckmyn
Pages: 129 - 133 - Child-onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13(2018)
Authors: An-Sofie Schelpe, Elien Roose, Hans Deckmyn, Simon De Meyer, Karen Vanhoorelbeke
Pages: 1 - 9 - An open conformation of ADAMTS13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura(2018)
Authors: Elien Roose, An-Sofie Schelpe, Marijke Peetermans, Peter Verhamme, Hans Deckmyn, Simon De Meyer, Karen Vanhoorelbeke
Pages: 378 - 388
Patents
1 - 5 of 5
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
- Compositions comprising adamts13 for use in methods for the recanalization of occluded blood vessels in an infarction (Inventor)
- Compositions comprising adamts13 for use in methods for the recanalization of occluded blood vessels in an infarction (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)